Cardinal Health Recalls CATAPRES-TTS-2 Patches Due to Temperature Excursions
Cardinal Health is recalling CATAPRES-TTS-2 adhesive patches due to intermittent exposure to temperature excursions during storage. The affected units were distributed in Florida, Georgia, and South Carolina.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, but the source text does not report any illnesses, injuries, or hospitalizations. The hazard is a storage deviation (temperature excursion) without reported harm, fitting the criteria for a moderate severity score.
Plain-English summary
Cardinal Health Inc. is recalling 17 units of CATAPRES-TTS-2 1X4 adhesive patches (NDC/UPC 597003234) due to CGMP deviations. The recall is caused by intermittent exposure to temperature excursions during storage.
The affected product is a prescription medication (RX) identified by code 1905666/2. The distribution pattern for these units includes Florida, Georgia, and South Carolina.
Consumers with this product should stop using it and contact their healthcare provider or pharmacist for further instructions.
The recalled product
- Product
- CATAPRES-TTS-2 1X4; NDC/UPC 597003234; RX; ADHESIVE PATCHES
- Manufacturer
- Cardinal Health Inc.
- Category
- Drug — Adhesive Patches
- Affected units
- 17
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- 1905666/2
Distribution
Part of a larger recall action
This product is one of 198 recalled by Cardinal Health Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 198 products in this recall →Related recalls
Same manufacturer · Cardinal Health Inc.
See all →- HighEnoxaparin syringe bags recalled after being labeled with the wrong strength
FDA (Drugs) · 2025-09-03
- ModerateXolair auto-injectors exposed to temperatures outside labeled storage requirements
FDA (Drugs) · 2025-08-13
- ModerateRecombinate antihemophilic factor vials exposed to temperatures outside labeled storage
FDA (Drugs) · 2025-08-13
- ModerateXolair 75 mg syringes exposed to temperatures outside labeled storage requirements
FDA (Drugs) · 2025-08-13
- ModerateWegovy injection recalled due to temperature exposure during shipping
FDA (Drugs) · 2025-05-07
Same hazard · temperature excursion
See all →- ModerateCyclophosphamide injection vials recalled after a transportation temperature excursion
FDA (Drugs) · 2025-09-24
- ModerateProlia prefilled syringes recalled after potential temperature excursions during transit delays
FDA (Drugs) · 2025-07-30
- ModerateBenlysta vials recalled after potential temperature excursions during transit delays
FDA (Drugs) · 2025-07-30
- ModerateEvenity prefilled syringes recalled after potential temperature excursions during transit delays
FDA (Drugs) · 2025-07-30
Similar recalls
- ModerateChlorthalidone Tablets Recalled for Temperature Storage Deviations
FDA (Drugs) · 2024-01-03
- ModeratePrescription Aripiprazole tablets recalled nationwide for storage temperature deviation
FDA (Drugs) · 2024-01-03
- HighOneTouch Ultra Test Strips Recalled for Potential Inaccurate Glucose Readings
FDA (Devices) · 2021-06-30
- HighFDA Recalls Lisinopril and Hydrochlorothiazide Tablets Due to Temperature Storage Deviations
FDA (Drugs) · 2024-01-03
- ModerateCitalopram Tablets Recalled for Temperature Storage Deviation
FDA (Drugs) · 2024-01-03
- HighMetoprolol Succinate Extended-Release Tablets Recalled for Storage Temperature Deviations
FDA (Drugs) · 2024-01-03